mk-2206
Minimally Invasive Lung Adenocarcinoma
Explore 9 assets in Minimally Invasive Lung Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01294306CT.gov MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Minimally Invasive Lung Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mk-2206 (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Carboplatin | NRG Oncology | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
| Metformin | NRG Oncology | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Etoposide | National Cancer Institute (NCI) | P2 | CCC |
| Docetaxel | National Cancer Institute (NCI) | P2 | CCC |
| Nivestim | National Cancer Institute (NCI) | P2 | CCC |
+2 more in the Minimally Invasive Lung Adenocarcinoma cohort
Other indications for mk-2206
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | BB · 64 |
| Breast Carcinoma | — | P2 | B · 57 |
| Prostate Cancer | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. mk-2206 in Minimally Invasive Lung Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mk-2206-minimally-invasive-lung-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →